Literature DB >> 8164037

Ki-1/CD30+ (anaplastic) large-cell lymphoma: maturation of a clinicopathologic entity with prospects of effective therapy.

M E Kadin.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 8164037     DOI： 10.1200/JCO.1994.12.5.884

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

1.  ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).

Authors:  G W Colleoni; J A Bridge; B Garicochea; J Liu; D A Filippa; M Ladanyi
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis.

Authors:  M Beylot-Barry; L Lamant; B Vergier; A de Muret; S Fraitag; B Delord; P Dubus; L Vaillant; M Delaunay; G MacGrogan; C Beylot; A de Mascarel; G Delsol; J P Merlio
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

3.  Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis.

Authors:  D Bischof; K Pulford; D Y Mason; S W Morris
Journal:  Mol Cell Biol       Date:  1997-04       Impact factor: 4.272

4.  Arthritis as a presenting feature of non-Hodgkin's lymphoma.

Authors:  F Falcini; M Bardare; R Cimaz; A Lippi; F Corona
Journal:  Arch Dis Child       Date:  1998-04       Impact factor: 3.791

5.  Low frequency association of the t(2;5)(p23;q35) chromosomal translocation with CD30+ lymphomas from American and Asian patients. A reverse transcriptase-polymerase chain reaction study.

Authors:  J R Lopategui; L H Sun; J K Chan; M J Gaffey; H F Frierson; C Glackin; L M Weiss
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

6.  Combination of dexamethasone, high-dose cytarabine, and carboplatin is effective for advanced large-cell non-Hodgkin lymphoma of childhood.

Authors:  John T Sandlund; Victor M Santana; Melissa M Hudson; Mihaela Onciu; David Head; Daryl J Murry; Raul Ribeiro; Dana Wallace; Renee Rencher; Ching-Hon Pui
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

7.  Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity.

Authors:  R Y Bai; P Dieter; C Peschel; S W Morris; J Duyster
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

8.  A novel model of alternative NF-κB pathway activation in anaplastic large cell lymphoma.

Authors:  Hongbo Wang; Wei Wei; Jing-Ping Zhang; Zhihui Song; Yangyang Li; Wenming Xiao; Yijun Liu; Mu-Sheng Zeng; Michael N Petrus; Craig J Thomas; Marshall E Kadin; Masao Nakagawa; Thomas A Waldmann; Yibin Yang
Journal:  Leukemia       Date:  2020-11-12       Impact factor: 12.883

9.  PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.

Authors:  Daniela Laimer; Helmut Dolznig; Karoline Kollmann; Paul W Vesely; Michaela Schlederer; Olaf Merkel; Ana-Iris Schiefer; Melanie R Hassler; Susi Heider; Lena Amenitsch; Christiane Thallinger; Philipp B Staber; Ingrid Simonitsch-Klupp; Matthias Artaker; Sabine Lagger; Suzanne D Turner; Stefano Pileri; Pier Paolo Piccaluga; Peter Valent; Katia Messana; Indira Landra; Thomas Weichhart; Sylvia Knapp; Medhat Shehata; Maria Todaro; Veronika Sexl; Gerald Höfler; Roberto Piva; Enzo Medico; Bruce A Ruggeri; Mangeng Cheng; Robert Eferl; Gerda Egger; Josef M Penninger; Ulrich Jaeger; Richard Moriggl; Giorgio Inghirami; Lukas Kenner
Journal:  Nat Med       Date:  2012-10-14       Impact factor: 53.440
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.